Patient-Data-Sovereignty + Outcome-Procurement — Competitor Scan

Verdict (one line)

A. Clean white space. No 2026 startup combines all three legs of the wedge (patient-as-data-source-of-truth + value-based contracts on the panel + patient cash payouts from the savings pool). The closest competitor holds two of three legs in adjacent shapes, none holds the bundle.

The wedge, restated for scoring

The bet thesis (per the 2026-05-10 architecture doc) bundles three pieces in one structure:

1. Patient-as-data-source-of-truth (DS): patient holds a sovereign longitudinal health record - the platform's measurement layer is the patient's vault, not a hospital's EHR.
2. Value-based contract (VBC): the platform sits inside a downside-risk arrangement with payer (CMS innovation model, MA, commercial) tied to measured medical outcomes.
3. Patient cash payouts (PI): the savings pool is explicitly split with patients in cash (or cash-equivalent), structured to clear AKS / Beneficiary Inducement CMP under the Promotes-Access-to-Care exception or a similar safe harbor.

Anyone who has all three IS the competitor. Anyone with two of three is the closest analog and tells us what the white-space defense looks like.

Candidates (named, scored against DS / VBC / PI)

1. PicnicHealth (incl. ThumbPrint, Mar 2026)

• What. Patient-anchored longitudinal record platform. Patients sign a HIPAA release; PicnicHealth retrieves charts, paper, EHR, imaging from any site, normalizes, and gives the patient a unified record. ThumbPrint (launched Mar 2026) is the "patient-anchored alternative to tokenization" - a living, consented data asset for life-sciences research.
• DS: PARTIAL. Patient-anchored, consented, longitudinal. But the commercial flywheel is selling de-identified RWE to pharma sponsors, not making the patient the structural beneficiary of downstream value. Patient is data subject + consent-giver, not co-owner of the economic upside.
• VBC: NO. No payer-side value-based contracts. Sells to life-sciences (pharma research, real-world evidence).
• PI: NO. No cash payouts to patients. Patients get a free unified medical record (the value exchange).
• Score: 1/3. Closest on the data-sovereignty UX leg; nothing on payer or payouts.

2. Seqster

• What. "Patient-centric operating system" connecting longitudinal health data across EHRs, wearables, labs, genomics. "1-Click Patient" consent flow. Sells to life-sciences and to large enterprises (employers, payers) as data-aggregation infrastructure.
• DS: PARTIAL. Same shape as PicnicHealth - patient consent unlocks aggregation, but the customer is the enterprise, not the patient. Patient owns the access in name but does not direct the commercial flow.
• VBC: NO. Infrastructure layer; doesn't take payer risk.
• PI: NO. No patient payouts.
• Score: 1/3. Adjacent-but-not-on-thesis (same category as Truveta/Verana/Komodo per parent brief).

3. Particle Health

• What. API-layer for longitudinal patient health data via the QHIN/TEFCA stack. Sells to digital health, payers, providers, and AI startups. "Actionable data for healthcare innovators" - a developer platform.
• DS: NO. Not patient-anchored. It's an infrastructure broker on top of the QHIN federation. The patient is the data subject, not the platform's principal.
• VBC: NO. Infra layer.
• PI: NO.
• Score: 0/3. Pure infra. Not even on the data-sovereignty thesis - it's the opposite shape (institutional broker).

4. Datavant

• What. Healthcare data collaboration platform. PPRL + tokenization moves 60M+ records/year across 70K+ hospitals. Commercial broker.
• DS: NO. Patient does not direct it (per parent brief). Commercial broker, institution-anchored.
• VBC: NO. Infra.
• PI: NO.
• Score: 0/3. Same category as Truveta/Verana/Komodo. Anti-thesis on sovereignty.

5. Hu-manity.co

• What. Founded ~2018 on the explicit thesis "31st human right" - patients should own and sell their medical data. Built #My31 app + data-rights infrastructure.
• DS: PARTIAL. Strong rhetorical alignment with sovereignty thesis. But the operational reality: traction has been thin since 2020-2022; not a 2026 competitor in scale terms. App still up but commercial momentum unclear.
• VBC: NO. No value-based-care contract play.
• PI: PARTIAL-ASPIRATIONAL. The model assumed pharma would pay patients for data licensing. Has not produced material patient cash flows at scale.
• Score: 1.5/3 in thesis, 0.5/3 in execution. Cautionary tale - closest thesis match in the entire scan, but execution stalled. The wedge's defensibility cannot rest on rhetoric alone.

6. Embleema

• What. Healthcare blockchain network for patient-controlled health records. Patients can be paid in crypto for sharing data with researchers.
• DS: PARTIAL. Patient-anchored consent + control. Blockchain layer for tokenized consent.
• VBC: NO. No payer-side value-based contracts. Pivoted toward regulatory submissions / RWE for pharma.
• PI: PARTIAL. Crypto micropayments to patients for data sharing - this is the closest active patient-payout mechanism in the scan. But payouts are token-rewards for data-licensing transactions, not outcome-tied savings-share.
• Score: 2/3 in form, 0/3 in outcome-tied substance. Has the data-sovereignty + patient-payout legs but the payout is for data licensing, not outcomes. Misses the value-based-contract leg entirely. Fundamentally a research-data marketplace, not a care-economics restructure.

7. Health Wizz

• What. Patient "filing cabinet" app + bundled data-sale to pharma/research.
• DS: PARTIAL. Patient holds + bundles their own data.
• VBC: NO.
• PI: PARTIAL. Sells data; some revenue share to patient.
• Score: 1.5/3. Same shape as Embleema - data-broker model, not care-economics model. No payer leg.

8. Aledade

• What. Largest value-based-care enabler for independent primary care. 150+ VBC contracts, ~2M patient lives. Provider-facing analytics + ACO infrastructure.
• DS: NO. Provider/EHR-anchored; patient is not data principal.
• VBC: YES. Deep + mature. This is the strongest VBC operator in the scan.
• PI: NO. Savings flow to providers; patient is not in the savings split.
• Score: 1/3. Has the contract leg fully built, missing both other legs entirely. If RDCO competes here, Aledade is the partner shape, not the competitor shape.

9. Strive Health (~$550M raised)

• What. Kidney care value-based-care operator. Takes risk on CKD/ESRD panels under KCC and commercial contracts.
• DS: NO. Provider-anchored EHR + analytics, not patient-anchored.
• VBC: YES. Operator under KCC Global. Among the top 5 VBC startups by funding.
• PI: NO. Patient incentive program is care-coordination + access (e.g., transportation), not outcome-tied cash share.
• Score: 1/3. Direct analog of what Variant B (vertical operator) of the bet architecture would look like in cardiometabolic - but missing the sovereignty + payout legs. Strive proves the operator playbook works; doesn't hold the wedge.

10. OM1 / HealthVerity

• What. OM1 = outcomes-measurement intelligence cloud (provider-facing). HealthVerity = patient-data marketplace (broker).
• DS: NO (institution-anchored both).
• VBC: NO (analytics + data, not contracted risk).
• PI: NO.
• Score: 0/3. Same category as Truveta/Verana/Komodo. Confirms the parent brief's framing - the broker tier is crowded but anti-thesis.

11. Lifebit (named in adjacent searches)

• What. Federated computing + privacy-preserving analytics for clinical data. Compute-escrow infra (the third Holzum rail).
• DS: NO (institution-anchored federated nodes).
• VBC: NO.
• PI: NO.
• Score: 0/3 on the wedge. But it IS the closest commercial product on the compute escrow leg from the parent brief - candidate partner / vendor for Phase 2 infra.

12. Mayo Clinic Platform "Data Under Glass" + NVIDIA Clara FL

• What. Federated learning enclaves (Mayo + Google partnership; NVIDIA Clara FL = shipped product).
• Score: 0/3 on the wedge (institution-anchored research infrastructure). Vendor candidates, not competitors.

Tally

Nobody scores 3/3. Maximum observed score = 2/3 (Embleema), and that 2/3 is wrong-shape: the second "yes" is data-licensing micropayments, not outcome-tied savings-share inside a payer contract.

Cross-check vault vs web

• Convergence: The vault's 01-projects/data-marketplace/index.md was already exploring marketplace economics. Web confirms the data-marketplace shape (Datavant, HealthVerity, Embleema, Health Wizz) is well-trodden but anti-thesis on patient-controlled care economics.
• Convergence: Parent brief's framing of Truveta/Verana/Komodo as adjacent-not-on-thesis is correct and extends to the broader broker tier (Datavant, OM1, HealthVerity, Particle Health). All institution-anchored, all missing both other legs.
• Contradiction (small): Parent brief flagged "no analog for patient-side acquisition cost for a data-sovereignty-first care brand." This scan confirms it - because nobody is running this brand. PicnicHealth's CAC numbers (research-cohort recruitment, ~$200-500 per consented patient per condition) are the closest indirect comp.
• New signal not in parent brief: CMS ACCESS Model received 150+ approved applicants (per StatNews 2026-04-13). Categories named: mental health apps, wearable device makers, a Google-tied life-sciences company, heart-failure-management startups. Most participants had not previously served Medicare patients. This is the bid surface where competitor emergence is most likely - but the participant list isn't fully public yet, so we can't confirm whether any 3/3 competitor is hiding inside the 150. Follow-up: pull the CMS ACCESS approved-applicant list when it publishes; re-score against the wedge.
• New signal not in parent brief: Discovery Vitality + Apple Watch is repeatedly cited as the closest existing analog, but is fitness-activity-tied (steps, gym), not measured-medical-outcome-tied. Confirmed: Vitality is precedent, not competitor.

Verdict + RDCO mapping

Verdict: A. Clean white space. The exact bundle is uncontested in May 2026. The wedge holds.

Differentiation defense (the moat statement):

"We are the only platform where the patient is the structural data principal AND the patient is in the savings split AND the platform sits inside a value-based contract. Brokers (Datavant, Truveta, Komodo, Verana, OM1, HealthVerity, Particle Health) hold the data but not the patient. Aggregators (PicnicHealth, Seqster) hold the consent but not the economics. Data-marketplace plays (Embleema, Hu-manity, Health Wizz) hold the patient-payout but the payout is for data licensing, not outcomes. VBC operators (Aledade, Strive Health) hold the contract but not the sovereignty or the patient share."

Mapping to bet-architecture variants:

• Variant A (pure platform / SaaS). White space confirmation strengthens A as Phase-1 because we sell to VBC operators (Aledade-shape customers) the missing measurement + payout layer that nobody is currently providing them. Platform thesis: "we make Aledade-style operators able to do patient-payouts cleanly under AKS." Action: keep A as Phase-1 MVP. Add explicit sales conversation with one mid-size ACO operator in cardiometabolic to test WTP.
• Variant B (vertical operator). Strive Health is the analog. Capital intensity confirmed real. White space doesn't change B's calculus - still off the table at current capital state.
• Variant C (hybrid network operator). White space strengthens C because no orchestrator currently runs the bundle. Action: re-rank C above pure-A for Phase-2 if Phase-1 traction shows providers want the bundle, not just the platform. The original recommended-sequence stands but the C ramp is more competitive-defensible than initially scored.
• Variant D (cooperative). Hu-manity.co is the cautionary tale - thesis-pure, execution-stalled. Mission-aligned framing alone doesn't capitalize. Action: keep D on the parallel grant-application track but do NOT lead with D. Ride the bet on A/C economics first; D becomes a structural transition once unit economics are proven.

MVP scope unchanged. The Whoop MCP + Apple Health + outcome-measurement engine + payment-orchestration scope from the parent architecture is correct. White space confirms we are not late.

Phase-1 acceleration: YES, with one constraint. ACCESS Model May 15 2026 application deadline already closed for cohort-1, but cohort-2 follows. The market signal (150+ approved applicants, "exceeded expectations") confirms outcome-aligned-payment demand is concrete. Action: track cohort-2 timing; consider partnering with an ACCESS cohort-1 participant for Phase-1 MVP integration.

Kill? No. White space is a stronger signal to proceed than to kill.

Open follow-up questions surfaced

1. CMS ACCESS approved-applicant roster. When does the full participant list publish, and does any 3/3 competitor exist inside the 150? (StatNews flagged "150+ approved" but didn't enumerate.)
2. Embleema ground truth. Is there a 2025-2026 Embleema product update where they added VBC-contract integration? Their 2/3 score is the closest in the scan; need to confirm they haven't pivoted into the wedge in the last 12 months.
3. Hu-manity.co status. Live or zombie? If live with new 2026 product, re-score. If zombie, the cautionary tale is sharper and we should harvest specific failure-mode lessons before Phase-1.
4. PicnicHealth ThumbPrint commercial trajectory. Mar 2026 launch is recent - if uptake is fast on the life-sciences side, they have the patient-anchored data layer that could be re-aimed at VBC if anyone hands them a contract. Watch for partnership announcements with VBC operators (Aledade, Strive, evolent, etc.) - that would shift their score from 1/3 toward 2/3 fast.
5. Aledade + patient-incentive integration. Has Aledade ever piloted patient-side savings-share inside any of its 150+ VBC contracts? If yes (even at small scale), they hold a half-built version of the bundle and become the most likely strategic acquirer / partner once we ship.
6. CMS ACCESS Model OAP calibration. Parent brief flagged this as "Federal Register watch." Now that 150+ applicants signed up, OAP rate-setting is no longer hypothetical. Action: schedule a follow-up scan once the first cohort starts paying (Aug-Sep 2026).
7. Discovery Vitality US expansion. Vitality has US footprint via John Hancock + Manulife life-insurance partnerships, not health insurance. Could they extend into US health-insurance VBC? If yes, they hold the patient-payout playbook and a brand. Watch for US health-side product launches.

Sources

Vault:

• Parent brief: ~/rdco-vault/06-reference/research/2026-05-10-healthcare-outcome-procurement-pioneering-provider.md
• Bet architecture: ~/rdco-vault/01-projects/health-and-longevity/2026-05-10-data-sovereignty-outcome-procurement-bet-architecture.md
• Data marketplace exploration: ~/rdco-vault/01-projects/data-marketplace/index.md

Web (accessed 2026-05-11):

• picnichealth.com + ThumbPrint launch (PR Newswire, Mar 2026)
• seqster.com (1-Click Patient platform)
• particlehealth.com (longitudinal API)
• datavant.com (collaboration platform)
• prnewswire.com Embleema healthcare blockchain network
• healthwealthsafe.com (patient-owned medical record bank concept)
• healthtechmagazines.com (transitioning to patient-owned data)
• statnews.com 2026-04-13 (CMS ACCESS 150+ approved applicants)
• statnews.com 2026-03-05 (patient health data as public utility - Alastair Thomson, ARPA-H)
• cms.gov ACCESS Model + ACCESS Technical FAQ
• atiadvisory.com 2026 CMS Innovation Center Outlook
• bvp.com State of Health AI 2026
• massivelybetterhealthcare.com 10 largest VBC startups (Aledade, Strive Health, etc.)
• fiercehealthcare.com (firms buying data directly from patients)
• onlinedegrees.sandiego.edu (Hu-manity.co, Embleema, Health Wizz overview)
• lifebit.ai healthcare data sovereignty compliance 2026